This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): IFNa-Kinoid, Interferon alpha Kinoid
Description: IFNa kinoid is an immunotherapy targeting interferon alpha (IFNa). It consists of an inactivated IFNa conjugated to a carrier protein and delivered with an adjuvant. IFNa kinoid is designed to elicit a natural polyclonal antibody response to IFNa leading to neutralization of the cytokine.
The drug is made using Stellar Biotechnologies' Keyhole Limpet Hemocyanin (KLH).
Tribute and POZEN
In June 2015, POZEN announced the acquisition of Tribute Pharmaceuticals Canada Inc. in a transaction valued at approximately US$146 million. Upon completion of the acquisition, which is expected to occur in the fourth quarter of 2015, the combined company will be named Aralez Pharmaceuticals plc and domiciled in Ireland. Upon closing, Aralez is expected to trade on NASDAQ and TSX.
In December 2015, POZEN and Tribute Pharmaceuticals Canada confirmed their merger plans and announced that they have entered into an amended agreement and plan of merger, which among other things, moves the domicile for their proposed parent company, Aralez Pharmaceuticals, from Ireland to Canada. The transaction is expected to close in the first quarter of 2016. It is a condition of closing that the common shares of Aralez be approved for listing on the NASDAQ and conditionally...See full deal structure in Biomedtracker
Partners: Aralez Pharmaceuticals Inc. Chong Kun Dang Pharmaceutical Corp. Stellar Biotechnologies, Inc.
IFNa Kinoid News
Pink Sheet Current Lupus Drugs In Clinical Development
Additional information available to subscribers only: